Price Chart

Profile

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
URL https://www.fennecpharma.com
Investor Relations URL https://investors.fennecpharma.com/
HQ State/Province North Carolina
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Mar. 21, 2025 (est.)
Last Earnings Release Nov. 07, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
URL https://www.fennecpharma.com
Investor Relations URL https://investors.fennecpharma.com/
HQ State/Province North Carolina
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Mar. 21, 2025 (est.)
Last Earnings Release Nov. 07, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A